No longer recruiting
Relapsing remitting MS
This trial is testing autologous (self) haematopoetic stem cells transplant for a variety of severe autoimmune diseases, including multiple sclerosis.
The treatment involves: treatment and collection and freezing of stem cells from the patient’s blood; chemotherapy (BEAM-ATG) to destroy the immune system; reinfusion of the patient’s own stem cells.
Full details of the treatment protocol can be found here in the Australian New Zealand Clinical Trials Registry.
General eligibility criteria must be met for all patients entering the trial. This includes general health criteria relating to cardiovascular, lung and liver health, absence of serious infectious diseases, negative pregnancy test for women, age between 18 and 65 years, and the ability to provide informed consent. Specific eligibility criteria must also be met for each disease type. For multiple sclerosis the eligibility criteria are as follows:
NB: The trial includes consideration of patients with highly active disease (determined by previous MRI prior to commencement of high efficacy treatment), where the long term immunosuppressive risk on treatment is determined to be of significance to patient’s morbidity/mortality as determined by a panel of physicians.
For full details of inclusion and exclusion criteria please visit the ANZCTR trial listing.
A full list of exclusion criteria can be found on the ANZCTR clinical trials database.
Dr John Moore
St Vincent’s Hospital, Sydney
390 Victoria St, Darlinghurst NSW 2010, Australia
Phone: 02 9355 5656
Fax: 02 9355 5735
For further details visit the ANZCTR trial listing.
"*" indicates required fields